Translational therapies for malignant pleural mesothelioma

References

• Pisick E, Salgia R. Molecular biology of malignant mesothelioma: a review. Hematol. Oncol. Clin. North Am.19(6), 997–1023 (2005).
   PubMed Web of Science ®Google Scholar
• Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology30(5), 403–418 (1997).
   PubMed Web of Science ®Google Scholar
• Cacciotti P, Barbone D, Porta C et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res.65(12), 5256–5262 (2005).
   PubMed Web of Science ®Google Scholar
• Kroczynska B, Cutrone R, Boccetta M et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelioma cells and causing mesothelioma in hamsters. Proc. Natl Acad. Sci. USA103(38), 14128–14133 (2006).
   PubMed Web of Science ®Google Scholar
• Cristaudo A, Foddis R, Vivaldi A et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case–control study. Cancer Res.65(8), 3049–3052 (2005).
   PubMed Web of Science ®Google Scholar
• De Luca A, Baldi A, Esposito V et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat. Med.3(8), 913–916 (1997).
   PubMed Web of Science ®Google Scholar
• Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. The SV40 large T antigen–p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res.68(4), 1022–1029 (2008).
   PubMed Web of Science ®Google Scholar
• Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin. Lung Cancer5(2), 98–106 (2003).
   PubMedGoogle Scholar
• Ramos-Nino M, Timblin C, Mossman B. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res.62(21), 6065–6069 (2002).
   PubMed Web of Science ®Google Scholar
• Yang H, Bocchetta M, Kroczynska B et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis Proc. Natl Acad. Sci. USA103(27), 10397–10402 (2006).
   PubMed Web of Science ®Google Scholar
• Xu A, Zhou H, Yu DZ, Hei TK. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ. Health Perspect.110(10), 1003–1008 (2002).
   PubMed Web of Science ®Google Scholar
• Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol.18(7), 1196–1202 (2007).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol.21(8), 1556–1561 (2003).
   PubMed Web of Science ®Google Scholar
• Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent development. Br. J. Cancer88(2), 167–174 (2003).
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer38(2), 111–121 (2002).
   PubMed Web of Science ®Google Scholar
• Fennell DA, Gaudino G, O’Byrne KJ et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat. Clin. Pract. Oncol.5(3), 136–147 (2008).
   PubMedGoogle Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21(14), 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer group and the National Cancer Institute of Canada. J. Clin. Oncol.23(28), 6881–6889 (2005).
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Favaretto AG et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol.24(9), 1443–1448 (2006).
   PubMed Web of Science ®Google Scholar
• Castagneto B, Botta M, Aitini E et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann. Oncol.19(2), 370–373 (2008).
   PubMed Web of Science ®Google Scholar
• Kratzke RA, Otterson GA, Lincoln CE et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Natl Cancer Inst.87(24), 1870–1875 (1995).
   PubMed Web of Science ®Google Scholar
• Papp T, Schipper H, Pemsel H et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesothelioma. Int. J. Oncol.18(2), 425–433 (2001).
   PubMed Web of Science ®Google Scholar
• Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin. Oncol.29(1), 2–17 (2002).
   PubMed Web of Science ®Google Scholar
• Procopio A, Marinacci R, Marinetti MR et al. SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Dev. Biol. Stand.94, 361–367 (1998).
   PubMedGoogle Scholar
• Manfredi JJ, Dong J, Liu WJ et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res.65(7), 2602–2609 (2005).
   PubMed Web of Science ®Google Scholar
• Prins JB, Williamson KA, Kamp MM et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int. J. Cancer75(4), 649–653 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng JQ, Jhanwar SC, Klein WM et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res.54(21), 5547–5551 (1994).
   PubMed Web of Science ®Google Scholar
• Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis23(7), 1127–1130 (2002).
   PubMed Web of Science ®Google Scholar
• Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J. Cell. Physiol.180(2), 150–157 (1999).
   PubMed Web of Science ®Google Scholar
• Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer38(2), 131–136 (2002).
   PubMed Web of Science ®Google Scholar
• López-Ríos F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res.66(6), 2970–2979 (2006).
   PubMed Web of Science ®Google Scholar
• Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev.13(1), 77–83 (2003).
   PubMed Web of Science ®Google Scholar
• Yang CT, You L, Yeh CC et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J. Natl Cancer Inst.92(8), 636–641 (2000).
   PubMed Web of Science ®Google Scholar
• Rippo MR, Moretti S, Vescovi S et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelioma cells. Oncogene23(47), 7753–7760 (2004).
   PubMed Web of Science ®Google Scholar
• Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem. Biophys. Res. Commun.304(3), 499–504 (2003).
   PubMed Web of Science ®Google Scholar
• Segers K, Ramael M, Singh SK et al. Immunoreactivity for Bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch.424(6), 631–634 (1994).
   PubMed Web of Science ®Google Scholar
• Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am. J. Physiol.275(1 Pt 1), L165–L171 (1998).
   PubMed Web of Science ®Google Scholar
• Soini Y, Pääkkö P. Apoptosis and expression of caspases 3, 6 and 8 in malignant non-Hodgkin’s lymphomas. APMIS107(11), 1043–1050 (1999).
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Cathomas R, Simões-Wüst AP et al. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int. J. Cancer106(2), 160–166 (2003).
   PubMed Web of Science ®Google Scholar
• Altieri DC. Cytokines, apoptosis, and survivin: three for tango. Cell Death Differ.8(1), 4–5 (2001).
   PubMed Web of Science ®Google Scholar
• Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest.108(7), 981–990 (2001).
   PubMed Web of Science ®Google Scholar
• Olie RA, Simoes-Wust AP, Baumann B et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res.60(11), 2805–2809 (2000).
   PubMed Web of Science ®Google Scholar
• Ishigami SI, Arii S, Furutani M et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer78(10), 1379–1384 (1998).
   PubMed Web of Science ®Google Scholar
• Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O’Byrne KJ. Tumour necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest124(5), 1916–1923 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards JG, Cox G, Andi A et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br. J. Cancer85(6), 863–868 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Vermeulen PB, Weyler J et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J. Pathol.182(2), 211–216 (1997).
   PubMed Web of Science ®Google Scholar
• Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma Chest128(5), 3382–3387 (2005).
   PubMed Web of Science ®Google Scholar
• Weyn B, Tjalma WA, Vermeylen P, van Daele A, Van Marck E, Jacob W. Determination of tumour prognosis based on angiogenesis-related vascular patterns measured by fractal and syntactic structure analysis. Clin. Oncol. (R. Coll. Radiol.)16(4), 307–316 (2004).
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.13(1), 9–22 (1999).
   PubMed Web of Science ®Google Scholar
• Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol.93(4), 468–475 (2001).
   Google Scholar
• Masood R, Kundra A, Zhu S et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer104(5), 603–610 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Weyler J, Martin MJH, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF β expression. J. Pathol.189(1), 72–78 (1999).
   PubMed Web of Science ®Google Scholar
• Ohta Y, Shridhar V, Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer81(1), 54–61 (1999).
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Edwards JG, Waller DA. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer45(Suppl. 1), S45–S48 (2004).
   Web of Science ®Google Scholar
• Catalano A, Romano M, Martinetti S, Procopio A. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene21(18), 2896–2900 (2002).
   PubMed Web of Science ®Google Scholar
• Langerak AW, van der Linden-van Beurden CA, Vesnel MA. Regulation of differential expression of platelet-derived growth factor α and β-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim. Biophys. Acta1305(1–2), 63–70 (1996).
   PubMed Web of Science ®Google Scholar
• Pogrebniak HW, Lubensky IA, Pass HI. Differential expression of platelet derived growth factor-β in malignant mesothelioma: a clue to future therapies? Surg. Oncol.2(4), 235–240 (1993).
   PubMed Web of Science ®Google Scholar
• Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB act as a chemoattractant for human malignant mesothelioma cells via PDGF receptor β-integrin α3β1 interaction. Clin. Exp. Metastasis16(6), 529–539 (1998).
   PubMed Web of Science ®Google Scholar
• Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am. J. Clin. Pathol.116(2), 253–262 (2001).
   PubMed Web of Science ®Google Scholar
• Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene24(50), 6080–6089 (2005).
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res.61(7), 2929–2934 (2001).
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjöblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res.62(19), 5476–5484 (2002).
   PubMed Web of Science ®Google Scholar
• Pietras K, Stumm M, Hubert M et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res.9(10 Pt 1), 3779–3787 (2003).
   PubMed Web of Science ®Google Scholar
• Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem.273(23), 14484–14494 (1998).
   PubMed Web of Science ®Google Scholar
• Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer61(6), 924–926 (1990).
   PubMed Web of Science ®Google Scholar
• Edwards JG, Swinson DE, Jones JL, Waller DA, O’Byrne KJ. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer54(3), 399–407 (2006).
   PubMed Web of Science ®Google Scholar
• Govindan R, Kratzke RA, Herndon JE et al. Gefitinib in patients with malignant mesothelioma (MM): a Phase II study by the Cancer and Leukemia Group B (CALGB 30101). Proc. Am. Soc. Clin. Oncol.22, 630; abstract 2535 (2003).
   Google Scholar
• Comoglio PM, Boccaccio C. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells1(4), 347–354 (1996).
   PubMed Web of Science ®Google Scholar
• Maestrini E, Tamagnone L, Longati P et al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc. Natl Acad. Sci. USA93(2), 674–678 (1996).
   PubMed Web of Science ®Google Scholar
• Abella JV, Peschard P, Naujokas MA et al. Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell Biol.25(21), 9632–9645 (2005).
   PubMed Web of Science ®Google Scholar
• Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev.27(1), 85–94 (2008).
   PubMed Web of Science ®Google Scholar
• Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J. Biol. Chem.266(33), 22087–22090 (1991).
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Andò M, Tamagnone L et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature391(6664), 285–288 (1998).
   PubMed Web of Science ®Google Scholar
• O’Brien LE, Tang K, Kats ES et al. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev. Cell7(1), 21–32 (2004).
   PubMed Web of Science ®Google Scholar
• Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell80(2), 179–185 (1995).
   PubMed Web of Science ®Google Scholar
• van der Voort R, Taher TE, Wielenga VJ et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem.274(10), 6499–6506 (1999).
   PubMed Web of Science ®Google Scholar
• Furge KA, Kiewlich D, Le P et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc. Natl Acad. Sci. USA98(19), 10722–10727 (2001).
   PubMed Web of Science ®Google Scholar
• Moghul A, Lin L, Beedle A et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene9(7), 2045–2052 (1994).
   PubMed Web of Science ®Google Scholar
• Jagadeeswaran R, Ma PC, Seiwert TY et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res.66(1), 352–361 (2006).
   PubMed Web of Science ®Google Scholar
• Roff M, Thompson J, Rodriguez MS et al. Role of IκBα ubiquitination in signal-induced activation of NF-7kgr;B in vivo. J. Biol. Chem.271(13), 7844–7850 (1996).
   PubMed Web of Science ®Google Scholar
• An B, Goldfarb RH, Simian R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induces apoptosis in transformed, but not normal, human fibroblast. Cell Death Differ.5(12), 1062–1075 (1998).
   PubMed Web of Science ®Google Scholar
• Miska EA. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev.15(5), 563–568 (2005).
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature435(7043), 834–838 (2005).
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA103(7), 2257–2261 (2006).
   PubMed Web of Science ®Google Scholar
• Guo Y, Chen Z, Zhang L et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res.68(1), 26–33 (2008).
   PubMed Web of Science ®Google Scholar
• Busacca S, Germano S, De Cecco L et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am. J. Respir. Cell Mol. Biol.42(3), 312–319 (2009).
   PubMed Web of Science ®Google Scholar
• Guled M, Lahti L, Lindholm PM et al.CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma. A miRNA microarray analysis. Genes Chromosomes Cancer48(7), 615–623 (2009).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Karrison T, Lu C et al. A multicenter, double-blind, placebo-controlled randomized Phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc. Am. Soc. Clin. Oncol.23(16S), 7019 (2005).
   Google Scholar
• Jackman DM, Kindler HL, Yeap BY et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer113(4) 808–814 (2008).
   PubMed Web of Science ®Google Scholar
• Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB2-neu receptor tyrosine kinase downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am. J. Pathol.151(6) 1523–1530 (1997).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res.9(4), 1546–1556 (2003).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Mininberg E, Henderson T et al. Phase I/II trial evaluating blockade of tumor blood supply and tumor cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur. J. Cancer1, S293 (2003).
   Google Scholar
• Kindler HL, Vogelzang NJ, Chien K et al. SU5416 in malignant mesothelioma: a Univeristy of Chicago Phase II consortium study. Proc. Am. Soc. Clin. Oncol.20, 1359 (2001).
   Google Scholar
• Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol.20(6), 1657–1667 (2002).
   PubMed Web of Science ®Google Scholar
• Nowak AK, Millward MJ, Francis R, Schaaf A, Musk AW, Byrne MJ. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J. Clin. Oncol.26(439S), 8063 (2008).
   Google Scholar
• Bold G, Altmann KH, Frei J et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem.43(16), 2310–2323 (2000).
   PubMed Web of Science ®Google Scholar
• Jahan TM, Gu L, Wang X et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a Phase II study by the Cancer and Leukemia group B (CALGB30107). Proc. Am. Soc. Clin. Oncol.24(18S), 7081 (2006).
   Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant mesothelioma (MM): a Phase II trial of the Cancer and Leukemia Group (CALGB 30307). J. Clin. Oncol.25(435S), 7707 (2007).
   Google Scholar
• Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer48(2), 291–296 (2005).
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Abraham R, Harvie R et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized Phase II studies. Lung Cancer41(Suppl. 2), S11 (2003).
   Google Scholar
• Millward M, Parnis F, Byrne M et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc. Am. Soc. Clin. Oncol.22, 912 (2003).
   Google Scholar
• Villano J, Husain AN, Stadler WM et al. A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). J. Clin. Oncol.22(Suppl.), 7200 (2004).
   Google Scholar
• Mathy A, Baas P, Dalesio O et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a Phase II trial. Lung Cancer50(1), 83–86 (2005).
   PubMed Web of Science ®Google Scholar
• Porta C, Mutti L, Tassi, G. Negative results of an Italian group for mesothelioma (G.I.Me.). Pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother. Pharmacol.59(1), 149–150 (2007).
   PubMed Web of Science ®Google Scholar
• Bertino P, Porta C, Barbone D et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax62(8), 690–695 (2007).
   PubMed Web of Science ®Google Scholar
• Jänne PA, Taffaro ML, Salgia R et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res.62(18), 5242–5247 (2002).
   PubMed Web of Science ®Google Scholar
• Garland L, Rankin C, Scott K et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol.25(17), 2406–2413 (2007).
   PubMed Web of Science ®Google Scholar
• Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int. J. Cancer118(2), 521–522 (2006).
   PubMed Web of Science ®Google Scholar
• Mikulski SM, Costanzi JJ, Vogelzang NJ et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol.20(1), 274–281 (2002).
   PubMed Web of Science ®Google Scholar
• Vogelzang N, Taub R, Shin D et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival. Proc. Am. Soc. Clin. Oncol.19(577A), 2274 (2000).
   Google Scholar
• Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res.10(12 Pt 1), 3937–3942 (2004).
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res.13(17), 5144–5149 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiang L, Hassan R et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin. Cancer Res.12(15), 4695–4701 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon GJ, Mani M, Maulik G et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother. Pharmacol.61(4), 549–558 (2008).
   PubMed Web of Science ®Google Scholar
• Rusch VW, Rosenzweig K, Venkatraman E et al. A Phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg.22(4), 788–795 (2001).
   Google Scholar